Organogenesis Holdings Inc. (ORGO)

NASDAQ: ORGO · IEX Real-Time Price · USD
2.735
+0.045 (1.67%)
May 24, 2024, 10:16 AM EDT - Market open
1.67%
Market Cap 362.58M
Revenue (ttm) 435.47M
Net Income (ttm) 5.82M
Shares Out 132.57M
EPS (ttm) 0.04
PE Ratio 67.25
Forward PE 12.32
Dividend n/a
Ex-Dividend Date n/a
Volume 30,852
Open 2.700
Previous Close 2.690
Day's Range 2.640 - 2.740
52-Week Range 1.960 - 4.705
Beta 1.60
Analysts Buy
Price Target 4.83 (+76.6%)
Earnings Date May 9, 2024

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered li... [Read more]

Sector Healthcare
Founded 1985
Employees 862
Stock Exchange NASDAQ
Ticker Symbol ORGO
Full Company Profile

Financial Performance

In 2023, ORGO's revenue was $433.14 million, a decrease of -3.94% compared to the previous year's $450.89 million. Earnings were $4.95 million, a decrease of -68.16%.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price forecast is $4.83, which is an increase of 76.60% from the latest price.

Price Target
$4.83
(76.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

22 days ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

5 weeks ago - GlobeNewsWire

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

7 weeks ago - GlobeNewsWire

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

3 months ago - GlobeNewsWire

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

3 months ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

3 months ago - GlobeNewsWire

ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO) ...

6 months ago - Business Wire

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

7 months ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

8 months ago - GlobeNewsWire

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

CANTON, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

8 months ago - GlobeNewsWire

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...

9 months ago - GlobeNewsWire

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

10 months ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

11 months ago - GlobeNewsWire

TipRanks reveals the top 10 health care sector analysts of the past decade

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

1 year ago - CNBC

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

1 year ago - GlobeNewsWire

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

CANTON, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

1 year ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

1 year ago - GlobeNewsWire

Organogenesis Applauds Findings from the Office of Inspector General

Transitioning all skin substitutes to ASP-based payments has the potential to substantially reduce Medicare Part B expenditures Transitioning all skin substitutes to ASP-based payments has the potenti...

1 year ago - GlobeNewsWire

Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

CANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

1 year ago - GlobeNewsWire

Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...

1 year ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Organogenesis Holdings Inc.

Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Organogenesis Holdings Inc. (NASDAQ: ORGO) on be...

1 year ago - Newsfile Corp

Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

1 year ago - GlobeNewsWire

Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

1 year ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

1 year ago - GlobeNewsWire